128 
‘‘(A) for each dose, the maximum amount 
of active pharmaceutical ingredient that acts as 
an opioid receptor antagonist as recommended 
by the Food and Drug Administration as an 
initial dose when administered by one of the ap-
proved, labeled routes of administration in 
adults; and 
‘‘(B) a minimum of two doses packaged to-
gether. 
‘‘(5) QUANTITIES AND TERMS OF DELIVERY.— 
Under contracts under this subsection— 
‘‘(A) the Secretary shall provide, consistent 
with paragraph (6), for the purchase and deliv-
ery on behalf of States and Indian tribes of 
quantities of opioid overdose reversal drug 
products; and 
‘‘(B) each State and Indian tribe, at the 
option of the State or tribe, shall be permitted 
to obtain additional quantities of opioid over-
dose reversal drug products (subject to amounts 
specified to the Secretary by the State or tribe 
in advance of negotiations) through purchasing 
the opioid overdose reversal drug products from 
the manufacturers at the applicable price nego-
tiated by the Secretary consistent with para-
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00128
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
129 
graph (3), if the State or tribe provides to the 
Secretary such information (at a time and man-
ner specified by the Secretary, including in ad-
vance of negotiations under paragraph (1)) as 
the Secretary determines to be necessary, to 
provide for quantities of opioid overdose rever-
sal drug products for the State or tribe to pur-
chase pursuant to this subsection and to deter-
mine annually the percentage of the opioid over-
dose reversal drug market that is purchased 
pursuant to this section and this subparagraph. 
The Secretary shall enter into the initial negotia-
tions not later than 180 days after the date of the 
enactment of this title. 
‘‘(6) CHARGES
FOR
SHIPPING
AND
HAN-
DLING.—The Secretary may enter into a contract 
referred to in paragraph (1) only if the manufac-
turer involved agrees to submit to the Secretary 
such reports as the Secretary determines to be ap-
propriate to assure compliance with the contract and 
if, with respect to a State program under this sec-
tion that does not provide for the direct delivery of 
qualified opioid overdose reversal drug products, the 
manufacturer involved agrees that the manufacturer 
will provide for the delivery of the opioid overdose 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00129
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
130 
reversal drug products on behalf of the State in ac-
cordance with such program and will not impose any 
charges for the costs of such delivery (except to the 
extent such costs are provided for in the price estab-
lished under paragraph (3)). 
‘‘(7) MULTIPLE SUPPLIERS.—In the case of the 
opioid overdose reversal drug product involved, the 
Secretary may, as appropriate, enter into a contract 
referred to in paragraph (1) with each manufacturer 
of the opioid overdose reversal drug product that 
meets the terms and conditions of the Secretary for 
an award of such a contract (including terms and 
conditions regarding safety and quality). With re-
spect to multiple contracts entered into pursuant to 
this paragraph, the Secretary may have in effect dif-
ferent prices under each of such contracts and, with 
respect to a purchase by States pursuant to para-
graph (4)(B), each eligible State may choose which 
of such contracts will be applicable to the purchase. 
‘‘(c) USE OF OPIOID OVERDOSE REVERSAL DRUG 
PRODUCT LIST.—Beginning not later than one year after 
the first contract has been entered into under this section, 
the Secretary shall use, for the purpose of the purchase, 
delivery, and administration of opioid overdose reversal 
drug products under this section, the list established (and 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00130
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
131 
periodically reviewed and, as appropriate, revised) by an 
advisory committee, established by the Secretary and lo-
cated within the Centers for Disease Control and Preven-
tion, which considers the cost effectiveness of each opioid 
overdose reversal drug product. 
‘‘(d) STATE DISTRIBUTION OF OPIOID OVERDOSE 
REVERSAL DRUG PRODUCTS.—States shall distribute 
opioid overdose reversal drug products received under this 
section to the following: 
‘‘(1) First responders, including— 
‘‘(A) all State, county, and local law en-
forcement departments; 
‘‘(B) all local fire departments, including 
career fire departments, combination fire de-
partments, and volunteer fire departments; and 
‘‘(C) all local emergency medical services 
organizations, including volunteer emergency 
medical services organizations. 
‘‘(2) Public entities with authority to administer 
local public health services, including all local health 
departments, for the purposes of making opioid over-
dose reversal drug products available to— 
‘‘(A) public and nonprofit entities, includ-
ing— 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00131
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
132 
‘‘(i) community-based organizations 
that provide substance use disorder treat-
ments or harm reduction services; 
‘‘(ii) nonprofit entities that provide 
substance use disorder treatments or harm 
reduction services; and 
‘‘(iii) faith based organizations that 
provide substance use disorder treatments 
or harm reduction services; 
‘‘(B) other areas of high need; and 
‘‘(C) the general public. 
‘‘(e) STATE REQUIREMENTS.—To be eligible to re-
ceive opioid overdose reversal drugs under this section, 
each State shall— 
‘‘(1) establish a program for distributing opioid 
overdose reversal drug products to first responders 
and entities with authority to administer local public 
health services, including local health departments; 
‘‘(2) beginning in the second year of the pro-
gram, demonstrate a distribution rate of a minimum 
of 90 percent of the opioid overdose reversal drug 
products received under this program; and 
‘‘(3) certify to the Secretary that the State has 
in place a Good Samaritan Law that ensures immu-
nity from prosecution, including from parole and 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00132
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
133 
probation violations, except that the State may apply 
to the Secretary for a waiver of the requirement of 
this paragraph, and such waiver if granted shall not 
be longer than 3 years in duration and may not be 
renewed; and 
‘‘(4) certify to the Secretary that the State has 
in place additional measures that enhance access to 
opioid overdose reversal drug products, such as laws 
that provide civil or disciplinary immunity for med-
ical personnel who prescribe an opioid overdose re-
versal drug product, Third Party Prescription Laws, 
Collaborative Practice Agreements, and Standing 
Orders. 
‘‘(f) INDIAN TRIBE REQUIREMENTS.—The Indian 
Health Service, in consultation with Indian tribes, shall 
determine any requirements that shall apply to Indian 
tribes receiving opioid overdose reversal drug products 
made available under this section. 
‘‘(g) DEFINITIONS.—For purposes of this section: 
‘‘(1) CAREER
FIRE
DEPARTMENT.—The term 
‘career fire department’ means a fire department 
that has an all-paid force of firefighting personnel 
other than paid-on-call firefighters. 
‘‘(2) COLLABORATIVE PRACTICE AGREEMENT.— 
The term ‘Collaborative Practice Agreement’ means 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00133
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
134 
an agreement under which a pharmacist operates 
under authority delegated by another licensed practi-
tioner with prescribing authority. 
‘‘(3) COMBINATION
FIRE
DEPARTMENT.—The 
term ‘combination fire department’ means a fire de-
partment that has paid firefighting personnel and 
volunteer firefighting personnel. 
‘‘(4) EMERGENCY
MEDICAL
SERVICE.—The 
term ‘emergency medical service’ means resources 
used by a public or private nonprofit licensed entity 
to deliver medical care outside of a medical facility 
under emergency conditions that occur as a result of 
the condition of the patient and includes services de-
livered (either on a compensated or volunteer basis) 
by an emergency medical services provider or other 
provider that is licensed or certified by the State in-
volved as an emergency medical technician, a para-
medic, or an equivalent professional (as determined 
by the State). 
‘‘(5) GOOD SAMARITAN LAW.—The term ‘Good 
Samaritan Law’ means a law that provides criminal 
immunity for a person who administers an opioid 
overdose reversal drug product, a person who, in 
good faith, seeks medical assistance for someone ex-
periencing a drug-related overdose, or a person who 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00134
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
135 
experiences a drug-related overdose and is in need of 
medical assistance and, in good faith, seeks such 
medical assistance, or is the subject of such a good 
faith request for medical assistance. 
‘‘(6) INDIANS.—The terms ‘Indian’, ‘Indian 
tribe’, ‘tribal organization’, and ‘Urban Indian 
Health Program’ have the meanings given such 
terms in section 4 of the Indian Health Care Im-
provement Act. 
‘‘(7) MANUFACTURER.—The term ‘manufac-
turer’ means any corporation, organization, or insti-
tution, whether public or private (including Federal, 
State, and local departments, agencies, and instru-
mentalities), which manufactures, imports, proc-
esses, or distributes under its label any opioid over-
dose reversal drug product. The term ‘manufacture’ 
means to manufacture, import, process, or distribute 
an opioid overdose reversal drug. 
‘‘(8) OPIOID OVERDOSE REVERSAL DRUG PROD-
UCT.—The term ‘opioid overdose reversal drug prod-
uct’ means a finished dosage form that has been ap-
proved by the Food and Drug Administration and 
that contains an active pharmaceutical ingredient 
that acts as an opioid receptor antagonist. The term 
‘opioid overdose reversal drug product’ includes a 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00135
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
136 
combination product, as defined in section 3.2(e) of 
title 21, Code of Federal Regulations. 
‘‘(9) STANDING
ORDER.—The term ‘standing 
order’ means a non-patient-specific order covering 
administration of medication by others to a patient 
who may be unknown to the prescriber at the time 
of the order. 
‘‘(10) THIRD PARTY PRESCRIPTION.—The term 
‘third party prescription’ means an order written for 
medication dispensed to one person with the inten-
tion that it will be administered to another person. 
‘‘(11) VOLUNTEER
FIRE
DEPARTMENT.—The 
term ‘volunteer fire department’ means a fire de-
partment that has an all-volunteer force of fire-
fighting personnel. 
‘‘(h) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this suc-
tion— 
‘‘(1) $500,000,000 for fiscal year 2020; 
‘‘(2) $500,000,000 for fiscal year 2021; 
‘‘(3) $500,000,000 for fiscal year 2022; 
‘‘(4) $500,000,000 for fiscal year 2023; 
‘‘(5) $500,000,000 for fiscal year 2024; 
‘‘(6) $500,000,000 for fiscal year 2025; 
‘‘(7) $500,000,000 for fiscal year 2026; 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00136
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
137 
‘‘(8) $500,000,000 for fiscal year 2027; 
‘‘(9) $500,000,000 for fiscal year 2028; and 
‘‘(10) $500,000,000 for fiscal year 2029. 
‘‘SEC. 3437. ADDITIONAL FUNDING FOR THE NATIONAL IN-
STITUTES OF HEALTH. 
‘‘There is authorized to be appropriated to the Na-
tional Institutes of Health for the purpose of conducting 
research on addiction and pain, including research to de-
velop overdose reversal drug products, non-opioid drug 
products and non-pharmacological treatments for address-
ing pain and substance use disorder, and drug products 
used to treat substance use disorder— 
‘‘(1) $700,000,000 for fiscal year 2020; 
‘‘(2) $700,000,000 for fiscal year 2021; 
‘‘(3) $700,000,000 for fiscal year 2022; 
‘‘(4) $700,000,000 for fiscal year 2023; 
‘‘(5) $700,000,000 for fiscal year 2024; 
‘‘(6) $700,000,000 for fiscal year 2025; 
‘‘(7) $700,000,000 for fiscal year 2026; 
‘‘(8) $700,000,000 for fiscal year 2027; 
‘‘(9) $700,000,000 for fiscal year 2028; and 
‘‘(10) $700,000,000 for fiscal year 2029. 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00137
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
138 
‘‘SEC. 3438. ADDITIONAL FUNDING FOR THE CENTERS FOR 
DISEASE CONTROL AND PREVENTION. 
‘‘(a) IMPROVED DATA COLLECTION AND PREVEN-
TION OF INFECTIOUS DISEASE TRANSMISSION.— 
‘‘(1) DATA COLLECTION.—The Centers for Dis-
ease Control and Prevention shall use a portion of 
the funding appropriated under this section to en-
sure that all States participate in the Enhanced 
State Opioid Overdose Surveillance program and to 
provide technical assistance to medical examiners 
and coroners to facilitate improved data collection on 
fatal overdoses through such program. 
‘‘(2) CENTERS
FOR
DISEASE
CONTROL
AND 
PREVENTION.—The Centers for Disease Control and 
Prevention shall use amounts appropriated under 
this section for the purpose of improving data on 
drug overdose deaths and non-fatal drug overdoses, 
surveillance related to addiction and substance use 
disorder, and the prevention of transmission of infec-
tious diseases related to substance use. 
‘‘(3) TRIBAL DATA.—Not later than 6 months 
after the date of enactment of this title, the Director 
of the Centers for Disease Control and Prevention 
shall consult with Indian tribes to develop and im-
plement strategies that improve surveillance and re-
porting of fatal overdose deaths among American In-
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00138
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
139 
dians and Alaska Natives, including strategies that 
reduce the underestimation of fatal overdose deaths 
among American Indians and Alaska Natives due to 
undersampling or racial misclassification in State 
and Federal public health surveillance systems. 
‘‘(b) CHILDHOOD TRAUMA.—The Centers for Disease 
Control and Prevention shall use a portion of the funding 
appropriated under this section to fund the surveillance 
and data collection activities described in section 7131 of 
the SUPPORT for Patients and Communities Act, includ-
ing to encourage all States to participate in collecting and 
reporting data on adverse childhood experiences through 
the Behavioral Risk Factor Surveillance System, the 
Youth Risk Behavior Surveillance System, and other rel-
evant public health surveys or questionnaires. 
‘‘(c) WORKER HEALTH RISKS.—The Centers for Dis-
ease Control and Prevention shall use a portion of the 
funding appropriated under this section for data collection 
and surveillance activities on substance use, substance use 
disorders, drug overdose deaths, and non-fatal drug 
overdoses among workers, and the factors and practices 
that contribute to such use, disorders, and overdoses, in-
cluding occupational injuries and illness as well as occupa-
tional exposure to opioids and other illicit and licit drugs. 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00139
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
141 
‘‘(1) PLANNING COUNCIL.—The term ‘planning 
council’ means the substance use planning council 
established under section 3402. 
‘‘(2) RECOVERY RESIDENCE.—The term ‘recov-
ery residence’ means a residential dwelling unit, or 
other form of group housing, that is offered or ad-
vertised through any means, including oral, written, 
electronic, or printed means, by any individual or en-
tity as a residence that provides an evidence-based, 
peer-supported living environment for individuals un-
dergoing any type of substance use disorder treat-
ment or who have received any type of substance use 
disorder treatment in the past 3 years, including 
medication assisted treatment. 
‘‘(3) STATE.— 
‘‘(A) IN
GENERAL.—The term ‘State’ 
means each of the 50 States, the District of Co-
lumbia, and each of the territories. 
‘‘(B) TERRITORIES.—The term ‘territory’ 
means each of American Samoa, Guam, the 
Commonwealth of Puerto Rico, the Common-
wealth of the Northern Mariana Islands, the 
Virgin Islands, the Republic of the Marshall Is-
lands, the Federated States of Micronesia, and 
Palau. 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00141
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
142 
‘‘(4) 
SUBSTANCE
USE
DISORDER
TREAT-
MENT.— 
‘‘(A) IN GENERAL.—The term ‘substance 
use disorder treatment’ means an evidence- 
based, professionally directed, deliberate, and 
planned regimen including evaluation, observa-
tion, medical monitoring, and rehabilitative 
services 
and 
interventions 
such 
as 
pharmacotherapy, mental health services, and 
individual and group counseling, on an inpa-
tient or outpatient basis, to help patients with 
substance use disorder reach remission and 
maintain recovery. 
‘‘(B) TYPES OF TREATMENT.—Substance 
use disorder treatments shall include the fol-
lowing: 
‘‘(i) Clinical stabilization services, 
which are evidence-based services provided 
in secure, acute care facilities (which may 
be referred to as ‘addictions receiving fa-
cilities’) that, at a minimum— 
‘‘(I) provide intoxication manage-
ment and stabilization services; 
‘‘(II) are operated 24 hours per 
day, 7 days per week; and 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00142
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
143 
‘‘(III) 
that 
serve 
individuals 
found to be substance use impaired. 
These can also be referred to as ‘Ad-
dictions receiving facilities’. 
‘‘(ii) Withdrawal management and de-
toxification, which is a medical service that 
is provided on an inpatient or an out-
patient basis to assist an individual in 
managing the process of withdrawal from 
the physiological and psychological effects 
of substance use disorder. 
‘‘(iii) All outpatient, residential, and 
inpatient services described in section 
1915(l)(4)(c) of the Social Security Act. 
‘‘(C) LIMITATION.—Substance use disorder 
treatment providers shall not include— 
‘‘(i) prevention only providers; and 
‘‘(ii) a private practitioner who is li-
censed by a State licensing board and 
whose practice is limited to non-intensive 
outpatient care. 
‘‘(5) SUBSTANCE USE DISORDER TREATMENT 
SERVICES.—The term ‘substance use disorder treat-
ment services’ means any prevention services, core 
medical services, recovery and support services, early 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00143
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
144 
intervention services, and harm reduction services 
authorized under this title.’’. 
SEC. 4. AMENDMENTS TO THE CONTROLLED SUBSTANCES 
ACT. 
(a) CERTIFICATIONS.—Part C of the Controlled Sub-
stances Act (21 U.S.C. 821 et seq.) is amended by adding 
at the end the following: 
‘‘CERTIFICATIONS RELATING TO DIVERSION CONTROLS 
AND MISBRANDING 
‘‘SEC. 313. (a) DEFINITIONS.—In this section— 
‘‘(1) the term ‘covered dispenser’— 
‘‘(A) means a dispenser— 
‘‘(i) that is required to register under 
section 302(a)(2); and 
‘‘(ii) dispenses a controlled substance 
in schedule II; and 
‘‘(B) does not include a dispenser that is— 
‘‘(i) registered to dispense opioid 
agonist treatment medication under section 
303(g)(1); and 
‘‘(ii) operating in that capacity; 
‘‘(2) the term ‘covered distributor’ means a dis-
tributor— 
‘‘(A) that is required to register under sec-
tion 302(a)(1); and 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00144
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
145 
‘‘(B) distributes a controlled substance in 
schedule II; 
‘‘(3) the term ‘covered manufacturer’ means a 
manufacturer— 
‘‘(A) that is required to register under sec-
tion 302(a)(1); and 
‘‘(B) manufactures a controlled substance 
in schedule II; 
‘‘(4) the term ‘covered officer’, with respect to 
a covered person means— 
‘‘(A) in the case of a covered person that 
is not an individual— 
‘‘(i) the chief executive officer of the 
covered person; 
‘‘(ii) the president of the covered per-
son; 
‘‘(iii) the chief medical officer of the 
covered person; or 
‘‘(iv) the chief counsel of the covered 
person; and 
‘‘(B) in the case of a covered person that 
is an individual, that individual; and 
‘‘(5) the term ‘covered person’ means— 
‘‘(A) a covered dispenser; 
‘‘(B) a covered distributor; or 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00145
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
146 
‘‘(C) a covered manufacturer. 
‘‘(b) CERTIFICATIONS
RELATING
TO
DIVERSION 
CONTROLS.—Not later than 180 days after the date of 
enactment of this section, and each year thereafter, each 
covered officer of a covered person shall submit to the At-
torney General, for each controlled substance in schedule 
II dispensed, distributed, or manufactured by the covered 
person, a certification— 
‘‘(1) signed by the covered officer; and 
‘‘(2) certifying that— 
‘‘(A) the covered person maintains effective 
controls against diversion of the controlled sub-
stance into channels other than legitimate med-
ical, scientific, research, or industrial channels; 
‘‘(B) all information contained in any 
record, inventory, or report required to be kept 
or submitted to the Attorney General by the 
covered person under section 307, or under any 
regulation issued under that section, is accu-
rate; and 
‘‘(C) the covered person is in compliance 
with all applicable requirements under Federal 
law relating to reporting suspicious orders for 
controlled substances. 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00146
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
147 
‘‘(c) 
CERTIFICATIONS
RELATING
TO
MIS-
BRANDING.— 
‘‘(1) IN GENERAL.—Not later than 180 days 
after the date of enactment of this section, and each 
year thereafter, each covered officer of a covered 
manufacturer shall submit to the Secretary, for each 
controlled substance in schedule II manufactured by 
the covered manufacturer, a certification— 
‘‘(A) signed by the covered officer; and 
‘‘(B) certifying that the controlled sub-
stance is not misbranded, as described in sec-
tion 502 of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 352). 
‘‘(2) NOTIFICATION TO THE ATTORNEY GEN-
ERAL.— 
‘‘(A) 
FAILURE
TO
SUBMIT
CERTIFI-
CATIONS.—Not later than 30 days after the 
date on which a covered officer of a covered 
manufacturer is required to submit a certifi-
cation under paragraph (1) and fails to do so, 
the Secretary shall notify the Attorney General 
of the failure by the covered officer to submit 
the certification. 
‘‘(B) FALSE
CERTIFICATIONS
RELATING 
TO
MISBRANDING.—Not later than 30 days 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00147
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
148 
after the date on which the Secretary becomes 
aware that a certification submitted under 
paragraph (1) contains a materially false state-
ment or representation relating to the mis-
branding of a controlled substance with respect 
to the year for which the certification is sub-
mitted, the Secretary shall notify the Attorney 
General that the certification contains the ma-
terially false statement or representation.’’. 
(b) OFFENSES.—Part D of title II of the Controlled 
Substances Act (21 U.S.C. 841 et seq.) is amended by 
adding at the end the following: 
‘‘CERTIFICATIONS BY COVERED OFFICERS 
‘‘SEC. 424. (a) DEFINITIONS.—In this section, the 
terms ‘covered dispenser’, ‘covered distributor’, ‘covered 
manufacturer’, ‘covered officer’, and ‘covered person’ have 
the meanings given those terms in section 313. 
‘‘(b) OFFENSES.— 
‘‘(1) FAILURE TO SUBMIT CERTIFICATIONS.— 
‘‘(A) CERTIFICATIONS
RELATING
TO
DI-
VERSION CONTROLS.—It shall be unlawful for a 
covered officer of a covered person to fail to 
submit a certification required under section 
313(b), without regard to the state of mind of 
the covered officer. 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00148
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
149 
‘‘(B) CERTIFICATIONS RELATING TO MIS-
BRANDING.—It shall be unlawful for a covered 
officer of a covered manufacturer to fail to sub-
mit a certification required under section 
313(c)(1), without regard to the state of mind 
of the covered officer. 
‘‘(2) SUBMISSION OF FALSE CERTIFICATIONS.— 
‘‘(A) FALSE CERTIFICATIONS RELATING TO 
DIVERSION CONTROLS.—It shall be unlawful for 
a covered officer of a covered person to submit 
a certification required under section 313(b), 
without regard to the state of mind of the cov-
ered officer, that contains a materially false 
statement or representation relating to the in-
formation required to be certified under that 
section for the year for which the certification 
is submitted. 
‘‘(B) FALSE
CERTIFICATIONS
RELATING 
TO MISBRANDING.—It shall be unlawful for a 
covered officer of a covered manufacturer to 
submit a certification required under section 
313(c)(1), without regard to the state of mind 
of the covered officer, that contains a materially 
false statement or representation relating to the 
misbranding of a controlled substance with re-
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00149
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
150 
spect to the year for which the certification is 
submitted. 
‘‘(c) PENALTIES.— 
‘‘(1) CIVIL PENALTIES.—Except as provided in 
paragraph (2), a covered officer who violates sub-
section (b) shall be subject to a civil penalty of not 
more than $25,000. 
‘‘(2) CRIMINAL PENALTIES.—A covered officer 
who knowingly violates subsection (b)(2) shall be 
subject to criminal penalties under section 403(d). 
‘‘(d) 
COMPREHENSIVE
ADDICTION
RESOURCES 
FUND.— 
‘‘(1) ESTABLISHMENT.—There is established in 
the Treasury a fund to be known as the ‘Com-
prehensive Addiction Resources Fund’. 
‘‘(2) TRANSFER OF AMOUNTS.—There shall be 
transferred to the Comprehensive Addiction Re-
sources Fund 100 percent of— 
‘‘(A) any civil penalty paid to the United 
States under this section; and 
‘‘(B) any fine paid to the United States 
under section 403(d) for a knowing violation of 
subsection (b)(2) of this section. 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00150
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
151 
‘‘(3) AVAILABILITY
AND
USE
OF
FUNDS.— 
Amounts transferred to the Comprehensive Addic-
tion Fund under paragraph (2) shall— 
‘‘(A) remain available until expended; and 
‘‘(B) be made available to supplement 
amounts appropriated to carry out title XXXIV 
of the Public Health Service Act.’’. 
(c) CRIMINAL PENALTIES.—Section 403 of the Con-
trolled Substances Act (21 U.S.C. 843) is amended— 
(1) in subsection (d)(1)— 
(A) by inserting ‘‘or knowingly violates sec-
tion 424(b)(2)’’ after ‘‘any person who violates 
this section’’; and 
(B) by striking ‘‘violation of this section’’ 
and inserting ‘‘such a violation’’; and 
(2) in subsection (f)— 
(A) in paragraph (1), by striking ‘‘or 416’’ 
and inserting ‘‘or section 416, or knowing viola-
tions of section 424(b)(2)’’; and 
(B) in paragraph (3), by inserting ‘‘or 
knowing violations of section 424(b)(2)’’ before 
the period at the end. 
(d) TECHNICAL AND CONFORMING AMENDMENTS.— 
The table of contents for the Comprehensive Drug Abuse 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00151
Fmt 6652
Sfmt 6201
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS
152 
Prevention and Control Act of 1970 (Public Law 91–513; 
84 Stat. 1236) is amended— 
(1) by inserting after the item relating to sec-
tion 311 the following: 
‘‘Sec. 312. Suspicious orders. 
‘‘Sec. 313. Certifications relating to diversion controls and misbranding.’’; 
and 
(2) by inserting after the item relating to sec-
tion 423 the following: 
‘‘Sec. 424. Certifications by covered officers.’’. 
(e) EFFECTIVE DATE.—The amendments made by 
subsections (b) and (c) of this section shall take effect on 
the date that is 180 days after the date of enactment of 
this Act. 
Æ 
VerDate Sep 11 2014 
05:52 May 12, 2019
Jkt 089200
PO 00000
Frm 00152
Fmt 6652
Sfmt 6301
\\ALPHA3\E\BILLS\H2569.IH
H2569
kjohnson on DSK79L0C42 with BILLS